185 related articles for article (PubMed ID: 28833045)
1. Pharmacokinetic variability of valproate in women of childbearing age.
Johannessen Landmark C; Burns ML; Baftiu A; Farmen AH; Lossius MI; Johannessen SI; Tomson T
Epilepsia; 2017 Oct; 58(10):e142-e146. PubMed ID: 28833045
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring.
Johannessen Landmark C; Farmen AH; Burns ML; Baftiu A; Lossius MI; Johannessen SI; Tomson T
Epilepsy Res; 2018 Mar; 141():31-37. PubMed ID: 29453075
[TBL] [Abstract][Full Text] [Related]
3. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Johannessen Landmark C; Heger K; Lund C; Burns ML; Bjørnvold M; Sætre E; Johannessen SI
Ther Drug Monit; 2020 Oct; 42(5):744-753. PubMed ID: 32558674
[TBL] [Abstract][Full Text] [Related]
5. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
[TBL] [Abstract][Full Text] [Related]
6. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.
Gidal BE; Pitterle ME; Spencer NW; Maly MM
J Clin Pharm Ther; 1995 Aug; 20(4):215-9. PubMed ID: 8557785
[TBL] [Abstract][Full Text] [Related]
7. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice.
Johannessen Landmark C; Beiske G; Baftiu A; Burns ML; Johannessen SI
Seizure; 2015 May; 28():88-91. PubMed ID: 25758302
[TBL] [Abstract][Full Text] [Related]
8. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
Galimberti CA; Mazzucchelli I; Arbasino C; Canevini MP; Fattore C; Perucca E
Epilepsia; 2006 Sep; 47(9):1569-72. PubMed ID: 16981874
[TBL] [Abstract][Full Text] [Related]
9. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
[TBL] [Abstract][Full Text] [Related]
10. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of valproate prescriptions in women of childbearing age in certain regions of Russia.
Kostev K; Osina G; Rider F; Guekht A
Epilepsy Behav; 2019 Dec; 101(Pt A):106584. PubMed ID: 31675601
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Burns ML; Baftiu A; Opdal MS; Johannessen SI; Landmark CJ
Ther Drug Monit; 2016 Jun; 38(3):350-7. PubMed ID: 26751267
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.
Svendsen T; Brodtkorb E; Reimers A; Molden E; Sætre E; Johannessen SI; Johannessen Landmark C
Epilepsy Res; 2017 Jan; 129():125-131. PubMed ID: 28043062
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
[TBL] [Abstract][Full Text] [Related]
16. Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy.
Dwivedi R; Gupta YK; Singh M; Joshi R; Tiwari P; Kaleekal T; Tripathi M
Seizure; 2015 Feb; 25():187-90. PubMed ID: 25455060
[TBL] [Abstract][Full Text] [Related]
17. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.
Cloyd JC; Dutta S; Cao G; Walch JK; Collins SD; Granneman GR;
Epilepsy Res; 2003 Feb; 53(1-2):19-27. PubMed ID: 12576164
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.
May TW; Boor R; Rambeck B; Jürgens U; Korn-Merker E; Brandt C
Ther Drug Monit; 2011 Apr; 33(2):214-21. PubMed ID: 21383651
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
Van Matre ET; Cook AM
Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
